Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System

Addiction

Volumn 108, Issue 1, 2013, Pages 203-210

  Meyer, Tamra E ^a   Taylor, Lockwood G ^a   Xie, Suji ^a   Graham, David J ^b   Mosholder, Andrew D ^b   Williams, James R ^b   Moeny, David ^b   Ouellet Hellstrom, Rita P ^b   Coster, Trinka S ^a  

^a Virginia Office of the Surgeon General   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Claims analysis; Cohort studies; Nicotine patch; Nicotine replacement products; Pharmacoepidemiology; Propensity score; Psychiatric diagnosis; Survival rate; Tobacco use cessation products; Varenicline

Indexed keywords

AMFEBUTAMONE; BENZAZEPINE DERIVATIVE; NICOTINE GUM; NICOTINIC AGENT; QUINOXALINE DERIVATIVE; VARENICLINE;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; FEMALE; HOSPITALIZATION; HUMAN; MALE; MENTAL DISEASE; METHODOLOGY; MIDDLE AGED; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY; SMOKING CESSATION; SOLDIER; STATISTICS; UNITED STATES;

ADULT; AGED; BENZAZEPINES; BUPROPION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; MILITARY PERSONNEL; NICOTINIC AGONISTS; QUINOXALINES; RETROSPECTIVE STUDIES; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; UNITED STATES; YOUNG ADULT;

EID: 84871708296     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.04024.x     Document Type: Article

References (25)

1. Food and Drug Administration (FDA). FDA approves novel medication for smoking cessation. 2006. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108651.htm (accessed 15 August 2012) (Archived at http://www.webcitation.org/69w5eyt4V on 15 August 2012).
2. Gonzales D., Rennard S. I., Nides M., Oncken C., Azoulay S., Billing C. B. etal. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47-55.
3. Nides M., Oncken C., Gonzales D., Rennard S., Watsky E. J., Anziano R. etal. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166: 1561-1568.
4. Cahill K., Stead L. F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011; 16: CD006103.
5. Food and Drug Administration (FDA). Early communication about an ongoing safety review of varenicline (marketed as Chantix). 2007. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070765.htm (accessed 15 August 2012) (Archived at http://www.webcitation.org/69w64F5mh).
6. Food and Drug Administration (FDA). Public Health Advisory: important information on Chantix (varenicline). 2008. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051136.htm (accessed 15 August 2012) (Archived at http://www.webcitation.org/69w81tM0i).
7. Federal Aviation Administration. Anti-smoking medicine Chantix banned. 2011. Available at: http://www.faa.gov/news/updates/?newsId=56363 (accessed 15 August 2012) (Archived at http://www.webcitation.org/69w89DSsK).
8. Food and Drug Administration (FDA). Public Health Advisory: FDA requires new boxed warnings for the smoking cessation drugs Chantix and Zyban. 2009. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm169988.htm (accessed 15 August 2012) (Archived at http://www.webcitation.org/69w8TR2DN).
9. Tonstad S., Davies S., Flammer M., Russ C., Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010; 33: 289-301.
10. Garza D., Murphy M., Tseng L.-J., Riordan H. J., Chatterjee A. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biol Psychiatry 2011; 69: 1075-1082.
11. Lasser K., Boyd J. W., Woolhandler S., Himmelstein D. U., McCormick D., Bor D. H. Smoking and mental illness. JAMA 2000; 284: 2606-2610.
12. Purvis T. L., Mambourg S. E., Balvanz T. M., Magallon H. E., Pham R. H. Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. Ann Pharmacother 2009; 43: 862-867.
13. McClure J. B., Swan G. E., Catz S. L., Jack L., Javitz H., McAfee T. etal. Smoking outcome by psychiatric history after behavioral and varenicline treatment. J Subst Abuse Treat 2010; 38: 394-402.
14. Smith R. C., Lindenmayer J.-P., Davis J. M., Cornwell J., Noth K., Gupta S. etal. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009; 110: 149-155.
15. Stapleton J. A., Watson L., Spirling L. I., Smith R., Milbrandt A., Ratcliffe M. etal. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008; 103: 146-154.
16. McClure J., Swan G., Jack L., Catz S., Zbikowski S., McAfee T. etal. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med 2009; 24: 563-569.
17. Campbell A. R., Anderson K. D. Mental health stability in veterans with posttraumatic stress disorder receiving varenicline. Am J Health Syst Pharm 2010; 67: 1832-1837.
18. Gunnell D., Irvine D., Wise L., Davies C., Martin R. M. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805.
19. US Department of Veterans Affairs. Varenicline criteria for prescribing. 2011. Available at: http://www.pbm.va.gov/CriteriaForUse.aspx (accessed 15 August 2012) (Archived at http://www.webcitation.org/69w8cAMFt).
20. Deyo R. A., Cherkin D. C., Ciol M. A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
21. Lacy C. F., Armstrong L. L., Goldman M. P., Lance L. L. Drug Information Handbook, 14th edn. Hudson: Lexi-Comp Inc.; 2006.
22. Brookhart M. A., Sturmer T., Glynn R. J., Rassen J., Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care 2010; 48: S114-120.
23. Brookhart M. A., Schneeweiss S., Rothman K. J., Glynn R. J., Avorn J., Sturmer T. Variable selection for propensity score models. Am J Epidemiol 2006; 163: 1149-1156.
24. Leuven E., Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. This version 4.0.3 01oct2010; 2003. Software available from http://ideas.repec.org/c/boc/bocode/s432001.html, accessed 15 August 2012 (Archived at http://www.webcitation.org/69wHPdPy6).
25. Faessel H., Ravva P., Williams K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2009; 31: 177-189.